There is growing evidence that tacit collusion can be autonomously achieved by machine learning technology, at least in some real-life examples identified in the literature and experimental settings. Although more work needs to be done to assess the competitive risks of widespread adoption of autonomous pricing agents, this is still an appropriate time to examine which possible remedies can be used in case competition law shifts towards the prohibition of tacit collusion. This is because outlawing such conduct is pointless unless there are suitable remedies that can be used to address the social harm. This article explores how fines and structural and behavioural remedies can serve to discourage collusive results while preserving the incentives to use efficiency-enhancing algorithms. We find that this could be achieved if fines and remedies can target structural conditions that facilitate collusion. In addition, the problem of unfeasibility of injunctions to remedy traditional price coordination changes with the use of pricing software, which in theory can be programmed to avoid collusive outcomes. Finally, machine-learning methods can be used by the authorities themselves as a tool to test the effects of any given combination of remedies and to estimate a more accurate competitive benchmark for the calculation of the appropriate fine.
The debate over whether, in the absence of overt communications, mere tacit coordination between competitors should be outlawed is neither new nor settled. Current technological developments in the field of artificial intelligence (AI) have added further complexity to the discussion, which has given rise to many works that explore the effects of the use of AI-powered pricing software on competition. This paper attempts to contribute to the debate by addressing some issues not covered in previous works. First, there are risks to consumer welfare associated with AI pricing software's capacity to solve uncertainty (for example, supra-competitive equilibria may not be disrupted by changes in demand). Second, the use of artificial neural networks can make detection of anticompetitive pricing patterns more difficult. On the other hand, if authorities can harness the power of the technology themselves, detection problems could be alleviated. Third, the black box argument may not be a problem in this application of artificial neural networks since the pricing software industry has been able to develop more transparent algorithms in response to market demands. Finally, the use of AI pricing software brings some changes to the debate on the feasibility of remedies to mere interdependence, although more work needs to be carried out in this area.
The purpose of this Q&A paper is to provide an overview of artificial intelligence* with a special focus on machine learning* as a currently predominant subfield thereof. Machine learning-based applications have been discussed intensely in legal scholarship, including in the field of intellectual property law, while many technical aspects remain ambiguous and often cause confusion. This text was drafted by the Research Group on the Regulation of the Digital Economy of the Max Planck Institute for Innovation and Competition in the pursuit of understanding the fundamental characteristics of artificial intelligence, and machine learning in particular, that could potentially have an impact on intellectual property law. As a background paper, it provides the technological basis for the Group's ongoing research relating thereto. The current version summarises insights gained from background literature research, interviews with practitioners and a workshop held in
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.